A significant study has reassured breastfeeding mothers that taking antidepressants does not compromise their child’s cognitive development. Research published in JAMA Network Open examined 97 mother-child pairs over nearly two decades, focusing on children who were exposed to selective serotonin reuptake inhibitors (SSRIs) during pregnancy. The findings indicate that exposure to these medications through breast milk does not lead to lower IQ scores compared to children who were not exposed.
The long-term study aimed to compare the cognitive abilities of children who were exposed to SSRIs both in utero and through breastfeeding against those who were only exposed in the womb. The results showed that the verbal and performance IQ scores of children breastfed while their mothers were on SSRIs were comparable to those not exposed. Specifically, children who were breastfed without postnatal SSRI exposure averaged an IQ score of 109, while those who were breastfed and exposed to SSRIs scored slightly lower at 106. This suggests that additional exposure via breast milk does not negatively impact IQ.
The concern surrounding the safety of SSRIs during pregnancy and breastfeeding has often led mothers to forgo necessary medication. SSRIs are commonly prescribed to treat conditions such as depression, anxiety, and bulimia. They function by preventing the reabsorption of serotonin in the brain, thereby keeping this critical neurotransmitter active. Although SSRIs have been shown to assist many individuals in managing their mental health, questions about their safety for breastfeeding mothers have persisted.
While SSRIs can transfer into breast milk, the dosage received by an infant is significantly lower than what a fetus would receive in utero. Previous studies have suggested minimal impact from maternal SSRI use during pregnancy on children’s cognitive abilities, but the effects of breastfeeding while on these medications had not been thoroughly investigated until now.
The research involved pregnant women participating in the MotherToBaby California cohort study, which ran from May 8, 1989 to April 14, 2008. The study categorized participants into three groups: those who were breastfed and exposed to SSRIs through breast milk, those who were breastfed without SSRI exposure, and those who were not breastfed at all. Cognitive abilities were assessed using standardized IQ tests when the children reached ages four to five.
These findings may offer comfort to mothers who are concerned about the implications of continuing SSRI treatment while breastfeeding. The researchers assert that their results, alongside other studies, should encourage mothers to maintain their necessary medication regimen postpartum without fear of adverse effects on their children.
As more research emerges, the dialogue surrounding mental health treatment during pregnancy and breastfeeding continues to evolve. This study provides crucial insights that can help inform healthcare decisions for mothers, ultimately supporting both maternal and infant health.
For further reading, refer to the original research by Essi Whaites Heinonen et al, titled “Cognitive Outcomes of Children Exposed to Selective Serotonin Reuptake Inhibitors Through Breast Milk,” published in JAMA Network Open.
